202 related articles for article (PubMed ID: 21943814)
1. Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma.
Hsieh MY; Lin ZY; Chen SH; Chuang WL
Kaohsiung J Med Sci; 2011 Oct; 27(10):431-6. PubMed ID: 21943814
[TBL] [Abstract][Full Text] [Related]
2. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
[TBL] [Abstract][Full Text] [Related]
3. Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma.
Lin CI; Lin ZY; Hsieh MY; Huang CF; Chen SH; Chuang WL
Kaohsiung J Med Sci; 2011 Dec; 27(12):554-9. PubMed ID: 22208538
[TBL] [Abstract][Full Text] [Related]
4. [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin].
Kawamura Y; Ikeda K; Kumada H
Gan To Kagaku Ryoho; 2010 Mar; 37(3):402-7. PubMed ID: 20332675
[TBL] [Abstract][Full Text] [Related]
5. Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma.
Nishikawa H; Osaki Y; Kita R; Kimura T; Ohara Y; Takeda H; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Nishiguchi S
Oncol Rep; 2014 Jan; 31(1):65-72. PubMed ID: 24220763
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma.
Lu W; Li YH; Yu ZJ; He XF; Chen Y; Zhao JB; Zhu ZY
Hepatogastroenterology; 2007; 54(77):1499-502. PubMed ID: 17708284
[TBL] [Abstract][Full Text] [Related]
7. Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization.
Lu W; Li YH; He XF; Zhao JB; Chen Y; Mei QL
Cardiovasc Intervent Radiol; 2008; 31(6):1133-40. PubMed ID: 18584240
[TBL] [Abstract][Full Text] [Related]
8. Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on T cell subsets in patients with hepatocellular carcinoma.
Lu W; Li YH; He XF; Chen Y; Zeng QL; Qiu YR
Di Yi Jun Yi Da Xue Xue Bao; 2002 Jun; 22(6):524-6. PubMed ID: 12297475
[TBL] [Abstract][Full Text] [Related]
9. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
Kawai S; Tani M; Okamura J; Ogawa M; Ohashi Y; Monden M; Hayashi S; Inoue J; Kawarada Y; Kusano M; Kubo Y; Kuroda C; Sakata Y; Shimamura Y; Jinno K; Takahashi A; Takayasu K; Tamura K; Nagasue N; Nakanishi Y; Makino M; Masuzawa M; Yumoto Y; Mori T; Oda T
Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-38-S6-45. PubMed ID: 9151915
[TBL] [Abstract][Full Text] [Related]
10. A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma.
Bayraktar Y; Balkanci F; Kayhan B; Uzunalimoglu B; Gokoz A; Ozisik Y; Gurakar A; Van Thiel DH; Firat D
Hepatogastroenterology; 1996; 43(9):681-7. PubMed ID: 8799415
[TBL] [Abstract][Full Text] [Related]
11. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors.
Lu W; Li Y; He X; Chen Y
Hepatogastroenterology; 2003; 50(54):2079-83. PubMed ID: 14696468
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study.
Lee HS; Kim JS; Choi IJ; Chung JW; Park JH; Kim CY
Cancer; 1997 Jun; 79(11):2087-94. PubMed ID: 9179054
[TBL] [Abstract][Full Text] [Related]
16. Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience.
Seki A; Hori S; Kobayashi K; Narumiya S
Cardiovasc Intervent Radiol; 2011 Jun; 34(3):557-65. PubMed ID: 20821211
[TBL] [Abstract][Full Text] [Related]
17. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
18. Risk factors associated with bile leakage after hepatic resection for hepatocellular carcinoma.
Lee CC; Chau GY; Lui WY; Tsay SH; King KL; Loong CC; Hsia CY; Wu CW
Hepatogastroenterology; 2005; 52(64):1168-71. PubMed ID: 16001654
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for the development of pulmonary oil embolism after transcatheter arterial chemoembolization of hepatic tumors.
Wu GC; Chan ED; Chou YC; Yu CY; Hsieh TY; Hsieh CB; Chian CF; Ke FC; Dai YL; Su WL
Anticancer Drugs; 2014 Sep; 25(8):976-81. PubMed ID: 24736105
[TBL] [Abstract][Full Text] [Related]
20. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
